MX2009011783A - Inhibidores de iap. - Google Patents
Inhibidores de iap.Info
- Publication number
- MX2009011783A MX2009011783A MX2009011783A MX2009011783A MX2009011783A MX 2009011783 A MX2009011783 A MX 2009011783A MX 2009011783 A MX2009011783 A MX 2009011783A MX 2009011783 A MX2009011783 A MX 2009011783A MX 2009011783 A MX2009011783 A MX 2009011783A
- Authority
- MX
- Mexico
- Prior art keywords
- iap
- inhibitors
- general formula
- compounds
- useful
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91501007P | 2007-04-30 | 2007-04-30 | |
| PCT/US2008/061891 WO2008134679A1 (en) | 2007-04-30 | 2008-04-29 | Inhibitors of iap |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011783A true MX2009011783A (es) | 2009-12-04 |
Family
ID=39926122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011783A MX2009011783A (es) | 2007-04-30 | 2008-04-29 | Inhibidores de iap. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8907092B2 (enExample) |
| EP (1) | EP2148858A4 (enExample) |
| JP (1) | JP5368428B2 (enExample) |
| KR (1) | KR20100024923A (enExample) |
| CN (1) | CN101687787A (enExample) |
| AR (1) | AR066348A1 (enExample) |
| AU (1) | AU2008245447C1 (enExample) |
| BR (1) | BRPI0809867A2 (enExample) |
| CA (1) | CA2683392A1 (enExample) |
| CL (1) | CL2008001234A1 (enExample) |
| IL (1) | IL201379A0 (enExample) |
| MX (1) | MX2009011783A (enExample) |
| NZ (2) | NZ598890A (enExample) |
| PE (2) | PE20090211A1 (enExample) |
| RU (1) | RU2491276C2 (enExample) |
| TW (1) | TWI432212B (enExample) |
| WO (1) | WO2008134679A1 (enExample) |
| ZA (1) | ZA200906946B (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| EA012810B1 (ru) | 2005-02-25 | 2009-12-30 | Тетралоджик Фармасеутикалс | Димерные ингибиторы ингибиторов белков апоптоза (iap) |
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| AU2006308453B9 (en) | 2005-10-25 | 2011-12-01 | Pharmascience Inc. | IAP BIR domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| MX2009000824A (es) | 2006-07-24 | 2009-02-04 | Tetralogic Pharmaceuticals Cor | Antagonistas dimericos de las proteinas inhibidoras de la apoptosis. |
| DK2240506T3 (da) * | 2008-01-11 | 2013-04-08 | Genentech Inc | IAP inhibitorer |
| WO2009094224A1 (en) | 2008-01-25 | 2009-07-30 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| US8835393B2 (en) | 2008-08-02 | 2014-09-16 | Genentech, Inc. | Inhibitors of IAP |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| JP2012516329A (ja) | 2009-01-30 | 2012-07-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用 |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN102458116B (zh) * | 2009-05-28 | 2014-12-31 | 泰特拉洛吉克药业公司 | Iap抑制剂 |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| EP2603214A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MX2013004003A (es) | 2010-10-13 | 2013-10-01 | Millenium Pharmaceuticals Inc | Heteroarilos y usos de los mismos. |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| NO2755614T3 (enExample) | 2012-01-03 | 2018-03-31 | ||
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| KR20150011822A (ko) | 2012-05-04 | 2015-02-02 | 노파르티스 아게 | Iap 억제제 요법을 위한 바이오마커 |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| MX366978B (es) | 2013-03-15 | 2019-08-01 | Novartis Ag | Conjugados de anticuerpo - farmaco. |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6768522B2 (ja) | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| MX2017001946A (es) | 2014-08-12 | 2017-06-19 | Novartis Ag | Conjugados de farmacos con anticuerpos anti-cdh6. |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| CR20180229A (es) | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| KR102920712B1 (ko) | 2017-05-24 | 2026-01-30 | 노파르티스 아게 | 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법 |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| US20200362058A1 (en) | 2017-05-24 | 2020-11-19 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
| JP7210483B2 (ja) | 2017-06-30 | 2023-01-23 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規アザキノリン誘導体 |
| US11161851B2 (en) * | 2017-11-06 | 2021-11-02 | Suzhou Pengxu Pharmatech Co. Ltd. | Processes to produce acalabrutinib |
| CN109836416B (zh) * | 2017-11-27 | 2023-02-03 | 苏州鹏旭医药科技有限公司 | 一种化合物的制备方法 |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| AU2019409132B2 (en) | 2018-12-21 | 2026-08-06 | Novartis Ag | Antibodies to PMEL17 and conjugates thereof |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| AU2020316096A1 (en) | 2019-07-25 | 2021-12-02 | Lanzatech, Inc. | Secondary acetate fermentation |
| JP2022542437A (ja) | 2019-08-02 | 2022-10-03 | ランティオペプ ベスローテン ヴェンノーツハップ | 癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| US12678509B2 (en) | 2019-11-08 | 2026-07-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (IAP) protein antagonists |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| US20230056604A1 (en) | 2020-01-20 | 2023-02-23 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| EP4168007A1 (en) | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AU2022258829A1 (en) | 2021-04-16 | 2023-10-26 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| JP2025524064A (ja) | 2022-07-26 | 2025-07-25 | ノバルティス アーゲー | Ａｋｒ１ｃ３依存性ｋａｒｓ阻害剤の結晶形態 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| JP2025535017A (ja) * | 2022-09-29 | 2025-10-22 | トラクト ファーマシューティカルズ インコーポレイテッド | Ｉａｐの阻害剤として有用な化合物及び組成物 |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE430062B (sv) * | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
| DE2714880A1 (de) * | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| FR2575753B1 (fr) * | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE3685626T2 (de) * | 1985-09-26 | 1993-01-28 | Beckmann Research Inst Of The | Sequenzierung von peptiden. |
| US4935494A (en) * | 1988-11-15 | 1990-06-19 | City Of Hope | C-terminal peptide and protein sequencing |
| CA2012306A1 (en) * | 1989-03-28 | 1990-09-28 | Werner Neidhart | Amino acid derivatives |
| DK167813B1 (da) * | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| WO1992001938A1 (en) | 1990-07-20 | 1992-02-06 | City Of Hope | Derivatization of c-terminal proline |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| SK56798A3 (en) * | 1995-10-30 | 1998-12-02 | Smithkline Beecham Corp | Protease inhibitors, pharmaceutical composition containing them and their use |
| WO1998046597A1 (en) | 1997-04-14 | 1998-10-22 | Emory University | Serine protease inhibitors |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6472172B1 (en) * | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
| CA2355215A1 (en) | 1998-12-28 | 2000-07-06 | Jim Wells | Identifying small organic molecule ligands for binding |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| US20020132786A1 (en) | 2000-08-24 | 2002-09-19 | Alnemri Emad S. | IAP binding peptide or polypeptide and methods of using the same |
| WO2004007529A2 (en) | 2002-07-15 | 2004-01-22 | The Trustees Of Princeton University | Iap binding compounds |
| US6992063B2 (en) * | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
| WO2002026775A2 (en) | 2000-09-29 | 2002-04-04 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
| WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
| AU2002253908A1 (en) | 2001-02-08 | 2003-02-17 | Thomas Jefferson University | A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis |
| SI1373263T1 (en) * | 2001-04-05 | 2005-04-30 | Torrent Pharmaceuticals Ltd | Heterocyclic compounds for aging-related and diabetic vascular complications |
| EP1421204A4 (en) | 2001-05-31 | 2004-12-15 | Univ Princeton | IAP-BINDING PEPTIDES AND ASSAYS FOR IDENTIFYING IAP-BINDING COMPOUNDS |
| US20030157522A1 (en) * | 2001-11-09 | 2003-08-21 | Alain Boudreault | Methods and reagents for peptide-BIR interaction screens |
| WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| CA2491041A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| AU2003290083A1 (en) | 2002-08-13 | 2004-03-11 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin's lymphomas |
| US20040171554A1 (en) * | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
| ATE400812T1 (de) | 2003-02-07 | 2008-07-15 | Genentech Inc | Zusammensetzungen und verfahren für verstärkte apoptose |
| IL156263A0 (en) | 2003-06-02 | 2004-01-04 | Hadasit Med Res Service | Livin-derived peptides, compositions and uses thereof |
| US7067274B2 (en) * | 2003-11-13 | 2006-06-27 | Genentech, Inc. | Compositions and methods for the screening pro-apoptotic compounds |
| CN1933847A (zh) | 2004-01-16 | 2007-03-21 | 密歇根大学董事会 | Smac肽模拟物及其应用 |
| BRPI0506883A (pt) | 2004-01-16 | 2007-05-29 | Univ Michigan | miméticos de smac conformacionalmente comprimidos e seus usos |
| EP1723122B1 (en) * | 2004-03-01 | 2014-11-19 | Board of Regents, The University of Texas System | Dimeric small molecule potentiators of apoptosis |
| US7345081B2 (en) | 2004-03-23 | 2008-03-18 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| PL2253614T3 (pl) * | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| KR100926203B1 (ko) * | 2004-07-02 | 2009-11-09 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| BRPI0513310A (pt) | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | análogos de tetrapeptìdeo |
| JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ結合性化合物 |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| EA012810B1 (ru) * | 2005-02-25 | 2009-12-30 | Тетралоджик Фармасеутикалс | Димерные ингибиторы ингибиторов белков апоптоза (iap) |
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| AU2006308453B9 (en) * | 2005-10-25 | 2011-12-01 | Pharmascience Inc. | IAP BIR domain binding compounds |
| WO2007106192A2 (en) * | 2005-12-19 | 2007-09-20 | Genentech, Inc. | Inhibitors of iap |
| TWI504597B (zh) * | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| MX2008012053A (es) | 2006-03-21 | 2008-12-17 | Joyant Pharmaceuticals Inc | Promotores de apoptosis de molecula pequeña. |
| US20100143499A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110217A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2007307763A1 (en) | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as IAP inhibitors |
| CN101605786A (zh) * | 2006-12-19 | 2009-12-16 | 健泰科生物技术公司 | 细胞凋亡抑制剂的咪唑并吡啶抑制剂 |
| DK2240506T3 (da) * | 2008-01-11 | 2013-04-08 | Genentech Inc | IAP inhibitorer |
| US8835393B2 (en) * | 2008-08-02 | 2014-09-16 | Genentech, Inc. | Inhibitors of IAP |
| JP2012500272A (ja) * | 2008-08-16 | 2012-01-05 | ジェネンテック， インコーポレイテッド | Ｉａｐのアザインドールインヒビター |
-
2008
- 2008-04-29 NZ NZ598890A patent/NZ598890A/xx not_active IP Right Cessation
- 2008-04-29 EP EP08747109A patent/EP2148858A4/en not_active Withdrawn
- 2008-04-29 CN CN200880022901A patent/CN101687787A/zh active Pending
- 2008-04-29 WO PCT/US2008/061891 patent/WO2008134679A1/en not_active Ceased
- 2008-04-29 CA CA002683392A patent/CA2683392A1/en not_active Abandoned
- 2008-04-29 CL CL200801234A patent/CL2008001234A1/es unknown
- 2008-04-29 JP JP2010506573A patent/JP5368428B2/ja not_active Expired - Fee Related
- 2008-04-29 AR ARP080101812A patent/AR066348A1/es not_active Application Discontinuation
- 2008-04-29 PE PE2008000757A patent/PE20090211A1/es not_active Application Discontinuation
- 2008-04-29 MX MX2009011783A patent/MX2009011783A/es not_active Application Discontinuation
- 2008-04-29 BR BRPI0809867-0A patent/BRPI0809867A2/pt not_active IP Right Cessation
- 2008-04-29 NZ NZ580226A patent/NZ580226A/xx not_active IP Right Cessation
- 2008-04-29 RU RU2009144094/04A patent/RU2491276C2/ru not_active IP Right Cessation
- 2008-04-29 PE PE2012001805A patent/PE20130150A1/es not_active Application Discontinuation
- 2008-04-29 US US12/598,027 patent/US8907092B2/en not_active Expired - Fee Related
- 2008-04-29 TW TW097115740A patent/TWI432212B/zh not_active IP Right Cessation
- 2008-04-29 KR KR1020097024828A patent/KR20100024923A/ko not_active Abandoned
- 2008-04-29 AU AU2008245447A patent/AU2008245447C1/en not_active Ceased
-
2009
- 2009-10-06 ZA ZA2009/06946A patent/ZA200906946B/en unknown
- 2009-10-11 IL IL201379A patent/IL201379A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2683392A1 (en) | 2008-11-06 |
| NZ580226A (en) | 2012-11-30 |
| US8907092B2 (en) | 2014-12-09 |
| JP5368428B2 (ja) | 2013-12-18 |
| AU2008245447B2 (en) | 2014-01-23 |
| TWI432212B (zh) | 2014-04-01 |
| KR20100024923A (ko) | 2010-03-08 |
| US20110077265A1 (en) | 2011-03-31 |
| EP2148858A4 (en) | 2011-01-26 |
| WO2008134679A1 (en) | 2008-11-06 |
| CN101687787A (zh) | 2010-03-31 |
| PE20090211A1 (es) | 2009-04-02 |
| AR066348A1 (es) | 2009-08-12 |
| BRPI0809867A2 (pt) | 2014-09-30 |
| RU2491276C2 (ru) | 2013-08-27 |
| AU2008245447A1 (en) | 2008-11-06 |
| RU2009144094A (ru) | 2011-06-10 |
| AU2008245447C1 (en) | 2014-11-20 |
| EP2148858A1 (en) | 2010-02-03 |
| JP2010526079A (ja) | 2010-07-29 |
| CL2008001234A1 (es) | 2008-09-22 |
| IL201379A0 (en) | 2010-05-31 |
| ZA200906946B (en) | 2011-05-25 |
| NZ598890A (en) | 2013-10-25 |
| TW200902067A (en) | 2009-01-16 |
| PE20130150A1 (es) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ580226A (en) | Dimer compounds as inhibitors of iap | |
| IL183514A0 (en) | Pyrrolidine inhibitors of iap | |
| TW200716606A (en) | Chemical compounds | |
| TW200800963A (en) | Chemical compounds | |
| PL1853602T3 (pl) | Związki chemiczne | |
| PT1853588E (pt) | Compostos químicos | |
| WO2007106192A3 (en) | Inhibitors of iap | |
| MX2009007713A (es) | Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas. | |
| TW200942533A (en) | Pyridyl inhibitors of hedgehog signalling | |
| MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
| TN2009000049A1 (en) | A pyrrolopyrazin as syk-kinase inhibitor | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| IL185275A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
| UA94749C2 (en) | Benzimidazole modulators of vr1 | |
| ATE523487T1 (de) | 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung | |
| MY153763A (en) | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | |
| MX2010007543A (es) | Inhibidores de iap. | |
| TW200745028A (en) | Novel sulphonylpyrroles | |
| GB2466912A (en) | Compositions and methods for treating lysosomal disorders | |
| WO2010021934A3 (en) | Azaindole inhibitors of iap | |
| TW200745027A (en) | Novel sulphonylpyrroles | |
| PL1758852T3 (pl) | Podstawione związki cyklopentenu | |
| TW200616977A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
| TW200740781A (en) | Novel compounds | |
| TNSN06260A1 (en) | Process for the preparation of tryptase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |